Literature DB >> 30071547

Epidemiology of Nontuberculous Mycobacteriosis.

Jennifer Adjemian1,2, Shelby Daniel-Wayman1, Emily Ricotta1, D Rebecca Prevots1.   

Abstract

Annual prevalence estimates for pulmonary nontuberculous mycobacterial (PNTM) disease in the contiguous United States range from 1.4 to 13.9 per 100,000 persons, while one study found an annual prevalence of up to 44 per 100,000 persons in Hawaii. PNTM prevalence varies by region, sex, and race/ethnicity, with higher prevalence among women and persons of Asian ancestry, as well as in the Southern United States and Hawaii. Studies consistently indicate that PNTM prevalence is increasing, with estimates ranging from 2.5 to 8% per year. Most PNTM disease is associated with Mycobacterium avium complex (MAC), although the proportion of disease attributed to MAC varies by region. Host factors identified as influencing disease risk include structural lung disease, immunomodulatory medication, as well as variants in connective tissue, mucociliary clearance, and immune genes. Environmental variables including measures of atmospheric moisture and concentrations of certain soil factors have also been shown to correlate with higher PNTM prevalence. Prevalence of extrapulmonary NTM disease is lower, stable, and associated with different risk factors, including primary immune deficiencies or HIV infection. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2018        PMID: 30071547     DOI: 10.1055/s-0038-1651491

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  19 in total

1.  Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease.

Authors:  Seong Mi Moon; In Young Yoo; Hee Jae Huh; Nam Yong Lee; Byung Woo Jhun
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.

Authors:  Dae Hun Kim; Byung Woo Jhun; Seong Mi Moon; Su-Young Kim; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 3.  Nontuberculous Mycobacteria and Heterologous Immunity to Tuberculosis.

Authors:  Javeed A Shah; Cecilia S Lindestam Arlehamn; David J Horne; Alessandro Sette; Thomas R Hawn
Journal:  J Infect Dis       Date:  2019-08-30       Impact factor: 5.226

4.  Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue.

Authors:  Véronique Dartois; Thomas Dick
Journal:  J Exp Med       Date:  2022-05-11       Impact factor: 17.579

5.  Novel Screening System of Virulent Strains for the Establishment of a Mycobacterium avium Complex Lung Disease Mouse Model Using Whole-Genome Sequencing.

Authors:  Koji Furuuchi; Shintaro Seto; Hajime Nakamura; Haruka Hikichi; Akiko Miyabayashi; Keiko Wakabayashi; Kazue Mizuno; Teruaki Oka; Kozo Morimoto; Minako Hijikata; Naoto Keicho
Journal:  Microbiol Spectr       Date:  2022-05-17

6.  Targeted next-generation sequencing: a Swiss army knife for mycobacterial diagnostics?

Authors:  Sagal Mohamed; Claudio U Köser; Max Salfinger; Wladimir Sougakoff; Scott K Heysell
Journal:  Eur Respir J       Date:  2021-03-18       Impact factor: 16.671

Review 7.  Pulmonary non-tuberculous mycobacterial infections: current state and future management.

Authors:  Kai Ling Chin; Maria E Sarmiento; Nadine Alvarez-Cabrera; Mohd Nor Norazmi; Armando Acosta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-18       Impact factor: 3.267

8.  Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease.

Authors:  Takanori Asakura; Shoji Suzuki; Hanako Fukano; Satoshi Okamori; Tatsuya Kusumoto; Yoshifumi Uwamino; Takunori Ogawa; Matsuo So; Shunsuke Uno; Ho Namkoong; Mitsunori Yoshida; Hirofumi Kamata; Makoto Ishii; Tomoyasu Nishimura; Yoshihiko Hoshino; Naoki Hasegawa
Journal:  Open Forum Infect Dis       Date:  2019-03-07       Impact factor: 3.835

9.  Evaluating the clinical significance of nontuberculous mycobacteria isolated from respiratory samples in Iran: an often overlooked disease.

Authors:  Zahra Mortazavi; Ahmadreza Bahrmand; Fatemeh Sakhaee; Reza Hosseini Doust; Farzam Vaziri; Seyed Davar Siadat; Abolfazl Fateh
Journal:  Infect Drug Resist       Date:  2019-07-03       Impact factor: 4.003

Review 10.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.